REASONS TO CONSIDER

Targeted Exposure
CHIH is a targeted play on the Health Care Sector in China – the world’s second largest economy by GDP.

ETF Efficiency
In a single trade, CHIH delivers access to dozens of health care companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.

All Share Exposure
The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings, among others.

PERFORMANCE (%)

<table>
<thead>
<tr>
<th></th>
<th>1M</th>
<th>YTD</th>
<th>1Y</th>
<th>3Y</th>
<th>Since Inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAV</td>
<td>4.76%</td>
<td>-12.81%</td>
<td>8.60%</td>
<td>-14.80%</td>
<td>-0.32%</td>
</tr>
<tr>
<td>Market Price</td>
<td>6.63%</td>
<td>-11.20%</td>
<td>10.00%</td>
<td>-14.77%</td>
<td>-0.18%</td>
</tr>
<tr>
<td>Index</td>
<td>4.86%</td>
<td>-12.35%</td>
<td>9.40%</td>
<td>-14.22%</td>
<td>0.39%</td>
</tr>
</tbody>
</table>

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. Click here for standard performance as of the most recent quarter-end.

INDUSTRY BREAKDOWN (%)

- Pharmaceuticals: Major 37.04%
- Biotechnology 32.73%
- Pharmaceuticals: Other 9.96%
- Medical Specialties 7.88%
- Pharmaceuticals: Generic 7.40%
- Hospital/Nursing Management 1.68%
- Miscellaneous Commercial Services 0.98%
- Chemicals: Specialty 0.97%
- Medical Distributors 0.39%
- Others* 0.97%

* Apparel/Footwear 0.36%, Services to the Health Industry 0.32%, Medical/Nursing Services 0.29%

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

TOP 10 HOLDINGS (%)

<table>
<thead>
<tr>
<th>Holdings Subject to Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wuxi Biologics Cayman Inc</td>
</tr>
<tr>
<td>Beigene Ltd</td>
</tr>
<tr>
<td>Cspc Pharmaceuticals</td>
</tr>
<tr>
<td>Innovent Biologics Inc</td>
</tr>
<tr>
<td>Wuxi Apptec Co Ltd-h</td>
</tr>
<tr>
<td>Sino Biopharmaceutical</td>
</tr>
<tr>
<td>Legend Biotech Corp-adr</td>
</tr>
<tr>
<td>Genscript Biotech Corp</td>
</tr>
<tr>
<td>Sinopharm Group Co-h</td>
</tr>
<tr>
<td>Shenzhen Mindr-a</td>
</tr>
</tbody>
</table>

ETF Category: International Access ± China Sector
As of 10/31/2023

Key Information

- Inception Date: 12/07/2018
- Underlying Index: MSCI China Health Care 10/50 Index
- Number of Holdings: 77
- Assets Under Management: $9.01 mil
- Total Expense Ratio: 0.65%
- Distribution Frequency: Semi-Annually

Trading Details

- Ticker: CHIH
- CUSIP: 37954Y541
- Exchange: NYSE Arca
- Bloomberg IOPV Ticker: CHIHIV
- Index Ticker: NU722071

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. Click here for standard performance as of the most recent quarter-end.

Industry Breakdown (%)

- Pharmaceuticals: Major 37.04%
- Biotechnology 32.73%
- Pharmaceuticals: Other 9.96%
- Medical Specialties 7.88%
- Pharmaceuticals: Generic 7.40%
- Hospital/Nursing Management 1.68%
- Miscellaneous Commercial Services 0.98%
- Chemicals: Specialty 0.97%
- Medical Distributors 0.39%
- Others* 0.97%

* Apparel/Footwear 0.36%, Services to the Health Industry 0.32%, Medical/Nursing Services 0.29%

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.
DEFINITIONS

MSCI China Health Care 10/50 Index: The MSCI China Health Care 10/50 Index is designed to capture the large- and mid-cap segments of securities included in the MSCI China Index that are classified in the Health Care Sector as per the Global Industry Classification Standard (GICS). The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings (e.g., American Depository Receipts). Additionally, the Index utilizes a 10/50 concentration constraint whereby the weight of each group entity in the Index is capped at 10% and the cumulative weight of all group entities with a weight in excess of 5% does not exceed 50% of the Index by weight.

MSCI China Index: The MSCI China Index captures large and mid-cap representation across China A shares, H shares, B shares, Red chips, P chips and foreign listings (e.g., ADRs).

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHIH is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

Carefully consider the Fund’s investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund’s full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by MSCI, nor does MSCI make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with MSCI.